Products
Mecbotamab Biosimilar Monoclonal Antibody (AXL) for Research
Cat No.: GMP-Bios-INN-1281
Anti-AXL/UFO therapeutic antibody (Pre-made Mecbotamab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Mecbotamab (development code BA-3011) is a monoclonal antibody targeting AXL. It is developed by BioAtla for non-small cell lung cancer, ovarian cancer, and soft tissue sarcoma. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1281-1mg | 1mg | 3090 |
| GMP-Bios-INN-1281-10mg | 10mg | |
| GMP-Bios-INN-1281-100mg | 100mg | |
| GMP-Bios-INN-1281-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Mecbotamab biosimilar, Whole mAb, Anti-AXL/UFO Antibody: Anti-AXL/Tyrosine-protein kinase receptor UFO/AXL oncogene/ARK therapeutic antibody |
| INN Name | Mecbotamab |
| Target | AXL/UFO |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | BioAtla |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancer;Ovarian cancer;Soft tissue sarcoma;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
